Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • CSL Limited ADR News

    82,00 € 0,00% +0,00 €
    08:13:52 Uhr Frankfurt aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A115DF
    ISIN: US12637N2045
    US-Symbol: CSLLY
    Typ: Aktie

    CSL Limited ADR News

    24.04.24 - PR Newswire
    CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
    CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy PR Newswire
    19.03.24 - PR Newswire
    Ferinject® approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure
    Ferinject® approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure PR Newswire
    06.03.24 - PR Newswire
    CSL Seqirus is Fully Prepared to Implement the FDA's Vaccines and Related Biological Products Advisory Committee Trivalent Influenza Vaccines Strain Selection for the 2024/25 U.S. Season
    CSL Seqirus is Fully Prepared to Implement the FDA's Vaccines and Related Biological Products Advisory Committee Trivalent Influenza Vaccines Strain Selection for the 2024/25 ...
    12.02.24 - PR Newswire
    Half year reported NPATA US$2 billion¹,² Up 13% at constant currency³
    Half year reported NPATA US$2 billion¹,² Up 13% at constant currency³ PR Newswire
    12.02.24 - PR Newswire
    Half year reported NPATA US$2 billion¹,² Up 13% at constant currency³
    Half year reported NPATA US$2 billion¹,² Up 13% at constant currency³ PR Newswire
    11.02.24 - PR Newswire
    CSL Announces Top-line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I [human])
    CSL Announces Top-line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I [human]) PR Newswire
    05.02.24 - PR Newswire
    New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster
    New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster PR ...
    16.01.24 - PR Newswire
    Harris Poll Survey Finds People Receiving Treatment for CIDP Are Interested in Exploring More Convenient Treatment Options
    Harris Poll Survey Finds People Receiving Treatment for CIDP Are Interested in Exploring More Convenient Treatment Options PR Newswire
    15.01.24 - PR Newswire
    Swissmedic erteilt Zulassung für CSLs HEMGENIX® (Etranacogene Dezaparvovec) als erste Gentherapie für Hämophilie B
    Swissmedic erteilt Zulassung für CSLs HEMGENIX® (Etranacogene Dezaparvovec) als erste Gentherapie für Hämophilie B PR Newswire
    03.01.24 - PR Newswire
    CSL Behring Announces Availability of Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) 10g Prefilled Syringe
    CSL Behring Announces Availability of Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) 10g Prefilled Syringe PR Newswire
    21.12.23 - PR Newswire
    CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster
    CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-​Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-​Generation ...
    21.12.23 - PR Newswire
    CSL Seqirus Commends the National Advisory Committee on Immunization for Preferential Recommendation of Enhanced Influenza Vaccines for Adults 65 and Older
    CSL Seqirus Commends the National Advisory Committee on Immunization for Preferential Recommendation of Enhanced Influenza Vaccines for Adults 65 and Older Canada ...
    14.12.23 - PR Newswire
    CSL's Garadacimab, a First-in-Class Factor XIIa Inhibitor, Receives FDA and EMA Filing Acceptance
    CSL's Garadacimab, a First-​in-Class Factor XIIa Inhibitor, Receives FDA and EMA Filing Acceptance PR Newswire
    11.12.23 - PR Newswire
    CSL Behring's HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates at Three Years Post-Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B
    CSL Behring's HEMGENIX® (etranacogene dezaparvovec-​drlb) Demonstrates at Three Years Post-​Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus ...
    28.11.23 - PR Newswire
    Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the first Self-Amplifying mRNA vaccine approved for COVID in adults
    Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the first Self-​Amplifying mRNA vaccine approved for COVID in adults PR Newswire
    24.11.23 - PR Newswire
    Iron Deficiency Day 2023: CSL Vifor calls for access to iron deficiency diagnosis and treatment
    Iron Deficiency Day 2023: CSL Vifor calls for access to iron deficiency diagnosis and treatment PR Newswire
    27.10.23 - PR Newswire
    CSL and uniQure Win 2023 Prix Galien USA Award
    CSL and uniQure Win 2023 Prix Galien USA Award PR Newswire
    11.10.23 - PR Newswire
    New Data Presented at IDWeek 2023 Demonstrates Public Health Benefit and Cost Savings Associated with Cell-Based and Adjuvanted Influenza Vaccines
    New Data Presented at IDWeek 2023 Demonstrates Public Health Benefit and Cost Savings Associated with Cell-​Based and Adjuvanted Influenza Vaccines PR Newswire
    18.09.23 - PR Newswire
    CSL Seqirus Shares Data Demonstrating the Potential for Influenza Vaccination to Reduce the Burden on Healthcare Resources
    CSL Seqirus Shares Data Demonstrating the Potential for Influenza Vaccination to Reduce the Burden on Healthcare Resources PR Newswire
    28.08.23 - PR Newswire
    CSL Seqirus Announces Third U.S. Government Award in Relation to Influenza A(H5N8) Candidate Vaccine
    CSL Seqirus Announces Third U.S. Government Award in Relation to Influenza A(H5N8) Candidate Vaccine PR Newswire

    Newssuche

    Videos

    08:40 Uhr +11,66%
    Technical Trading: Gold Long freitags
    Gold Long Typ: Turbo Open End WKN: NG8DB8 Hebel: 27 Laufzeit: OpenEnd Einstieg: Market ... Mehr »